Reported 1 day ago
AstraZeneca's CFO, Aradhana Sarin, highlighted the company's record revenue in the US market, largely driven by cancer drug sales. In a discussion with Yahoo Finance, Sarin noted the company's strategy to focus on the US for growth, aiming to achieve $80 billion in revenue by 2030, with half from the US. She emphasized the innovative nature of the US healthcare system that facilitates faster access to new therapies for patients. Additionally, Sarin shared insights on AstraZeneca's approach to manage manufacturing in light of potential tariffs, ensuring a robust supply chain within the US.
Source: YAHOO